Terms: = Breast cancer AND HEY1, CHF-2, 23462, ENSG00000164683, HESR1, CHF2, HESR-1, MGC1274, HRT-1, OAF1, HERP2 AND Treatment
18 results:
1. Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.
Mehra T; Lupatsch JE; Kössler T; Dedes K; Siebenhüner AR; von Moos R; Wicki A; Schwenkglenks ME
PLoS One; 2024; 19(4):e0301271. PubMed ID: 38573891
[TBL] [Abstract] [Full Text] [Related]
2. Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis.
Gao W; Sun L; Gai J; Cao Y; Zhang S
PLoS One; 2024; 19(1):e0297260. PubMed ID: 38227591
[TBL] [Abstract] [Full Text] [Related]
3.
Chen B; Jiang K; Wang H; Miao L; Lin X; Chen Q; Jing L; Lu X
Front Biosci (Landmark Ed); 2023 Sep; 28(9):220. PubMed ID: 37796700
[TBL] [Abstract] [Full Text] [Related]
4. Causal Bayesian gene networks associated with bone, brain and lung metastasis of breast cancer.
Park SB; Hwang KT; Chung CK; Roy D; Yoo C
Clin Exp Metastasis; 2020 Dec; 37(6):657-674. PubMed ID: 33083937
[TBL] [Abstract] [Full Text] [Related]
5. 3-O-(E)-p-Coumaroyl betulinic acid possess anticancer activity and inhibit Notch signaling pathway in breast cancer cells and mammosphere.
Kushwaha PP; Singh AK; Shuaib M; Prajapati KS; Vardhan PS; Gupta S; Kumar S
Chem Biol Interact; 2020 Sep; 328():109200. PubMed ID: 32702347
[TBL] [Abstract] [Full Text] [Related]
6. Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/β-catenin signaling pathway by regulating WNT2.
Xiu DH; Liu GF; Yu SN; Li LY; Zhao GQ; Liu L; Li XF
J Exp Clin Cancer Res; 2019 Feb; 38(1):94. PubMed ID: 30791958
[TBL] [Abstract] [Full Text] [Related]
7. The adaptor SASH1 acts through NOTCH1 and its inhibitor DLK1 in a 3D model of lumenogenesis involving CEACAM1.
Stubblefield K; Chean J; Nguyen T; Chen CJ; Shively JE
Exp Cell Res; 2017 Oct; 359(2):384-393. PubMed ID: 28823832
[TBL] [Abstract] [Full Text] [Related]
8. [HIF-2α/Notch3 pathway mediates CoCl
Wang JG; Yuan L
Sheng Li Xue Bao; 2016 Dec; 68(6):783-789. PubMed ID: 28004073
[TBL] [Abstract] [Full Text] [Related]
9. Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.
Thounaojam MC; Dudimah DF; Pellom ST; Uzhachenko RV; Carbone DP; Dikov MM; Shanker A
Oncotarget; 2015 Oct; 6(32):32439-55. PubMed ID: 26431276
[TBL] [Abstract] [Full Text] [Related]
10. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity.
Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA
Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291
[TBL] [Abstract] [Full Text] [Related]
11. Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells.
Lee J; Sehrawat A; Singh SV
Breast Cancer Res Treat; 2012 Nov; 136(1):45-56. PubMed ID: 22965833
[TBL] [Abstract] [Full Text] [Related]
12. JAG2 induction in hypoxic tumor cells alters Notch signaling and enhances endothelial cell tube formation.
Pietras A; von Stedingk K; Lindgren D; Påhlman S; Axelson H
Mol Cancer Res; 2011 May; 9(5):626-36. PubMed ID: 21402725
[TBL] [Abstract] [Full Text] [Related]
13. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
Suter TM; Procter M; van Veldhuisen DJ; Muscholl M; Bergh J; Carlomagno C; Perren T; Passalacqua R; Bighin C; Klijn JG; Ageev FT; Hitre E; Groetz J; Iwata H; Knap M; Gnant M; Muehlbauer S; Spence A; Gelber RD; Piccart-Gebhart MJ
J Clin Oncol; 2007 Sep; 25(25):3859-65. PubMed ID: 17646669
[TBL] [Abstract] [Full Text] [Related]
14. Lessons learned from the WHI: HRT requires a cautious and individualized approach.
Aubuchon M; Santoro N
Geriatrics; 2004 Nov; 59(11):22-6. PubMed ID: 15615157
[TBL] [Abstract] [Full Text] [Related]
15. Influence of postmenopausal hormone replacement therapy on an estrogen metabolite biomarker of risk for breast cancer.
Alvarez-Vasquez RB; Axelrod D; Frenkel K; Newman MC; Sepkovic DW; Bradlow HL; Zumoff B
Horm Metab Res; 2003 Jun; 35(6):358-61. PubMed ID: 12920658
[TBL] [Abstract] [Full Text] [Related]
16. Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates.
Beckmann MW; Jap D; Djahansouzi S; Nestle-Krämling C; Kuschel B; Dall P; Brumm C; Bender HG
Oncology; 2001; 60(3):199-206. PubMed ID: 11340370
[TBL] [Abstract] [Full Text] [Related]
17. Patient knowledge about hormone replacement therapy: implications for treatment.
Connelly MT; Rusinak D; Livingston W; Raeke L; Inui TS
Menopause; 2000; 7(4):266-72. PubMed ID: 10914620
[TBL] [Abstract] [Full Text] [Related]
18. [Hormone substitution therapy during menopause. Increase of compliance].
Porzio G; Patacchiola F; Toro G; Moscarini M
Minerva Ginecol; 1997 Nov; 49(11):515-9. PubMed ID: 9489350
[TBL] [Abstract] [Full Text] [Related]
